Focused On-demand Library for DNA dC->dU-editing enzyme APOBEC-3G

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9HC16

UPID:

ABC3G_HUMAN

Alternative names:

APOBEC-related cytidine deaminase; APOBEC-related protein 9; CEM-15; Deoxycytidine deaminase

Alternative UPACC:

Q9HC16; B2RDR9; Q45F02; Q5TF77; Q7Z2N1; Q7Z2N4; Q9H9H8

Background:

DNA dC->dU-editing enzyme APOBEC-3G, also known as APOBEC-related cytidine deaminase, plays a pivotal role in inhibiting retrovirus replication and retrotransposon mobility. It achieves this through both deaminase-dependent and independent mechanisms, effectively targeting single-stranded DNA to induce G-to-A hypermutations in viral DNA. This enzyme exhibits potent antiviral activity against a range of viruses including Vif-deficient HIV-1, SIVs, HBV, EIAV, XMRV, and SFV.

Therapeutic significance:

Understanding the role of DNA dC->dU-editing enzyme APOBEC-3G could open doors to potential therapeutic strategies, particularly in the realm of antiviral drug development. Its unique mechanism of inducing viral DNA mutations presents a novel target for therapeutic intervention.